Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesNephrologymeridian finerenone (Kerendia) Coverage | OpenPaye…
    Ask Trek AI about this page
    CurrentmeridianPolicy MDN.CP.PMN.266

    Finerenone (Kerendia) — Coverage Criteria for CKD with Type 2 Diabetes

    Customize your policy alerts

    Sign up for meridian Policy MDN.CP.PMN.266 alerts

    Get alerted when Policy MDN.CP.PMN.266 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization criteria for finerenone (Kerendia) for adult members with chronic kidney disease associated with type 2 diabetes under Meridian (Medicaid) lines of business.

    Policy Summary
    Payermeridian
    PolicyFinerenone (Kerendia) — Coverage Criteria for CKD with Type 2 Diabetes
    Policy CodePolicy MDN.CP.PMN.266
    Change TypeNo material changes
    Effective DateAug 1, 2025
    Last ReviewJul 9, 2025
    Next Review Date
    Key ActionSubmit documentation (office notes, lab results) demonstrating the member meets all approval criteria for prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsApproval duration
    ≥18Minimum age
    ≥25eGFR threshold
    ≥30 mg/gUACR threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    20 mg
    Max daily dose

    Coverage Criteria for Finerenone (Kerendia)

    Initial Approval Criteria — Chronic Kidney Disease

    Covered when ALL of the following are met:

    Initial CKD coverage

    • Diagnosis of both chronic kidney disease (CKD) AND type 2 diabetes (T2D)
    • Age >= 18 years>=18
    • Renal function and albuminuria: Both: eGFR >= 25 mL/min/1.73 m2 AND urine albumin-to-creatinine ratio (UACR) >= 30 mg/geGFR >=25 mL/min/1.73 m2; UACR >=30 mg/g
    • Dose limit: Requested dose does not exceed both: 20 mg per day AND 1 tablet per day<=20 mg/day; <=1 tablet/day
    Operational documentation: Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria

    Requests lacking required documentation may be denied

    Continued Therapy — Chronic Kidney Disease

    Covered when ALL of the following are met:

    Continued therapy criteria

    • Prior receipt or continuity: Member is either currently receiving medication via the Centene benefit or previously met initial approval criteria; OR member is currently receiving medication and is enrolled in a state/product with continuity of care regulations

      Refer to state-specific addendums for continuity of care (CC.PHARM.03A/03B)

    • Response to therapy: Member is responding positively to therapy
    • Dose increase limit: If request is for a dose increase, the new dose does not exceed both: 20 mg per day AND 1 tablet per day<=20 mg/day; <=1 tablet/day

    Requests for finerenone (Kerendia) that are for non‑FDA approved indications and are not specifically addressed by this policy will not be authorized unless the provider submits sufficient documentation supporting safety and efficacy per applicable off‑label use policies. Refer to the plan off‑label use policies: CP.CPA.09 (commercial), HIM.PA.154 (health insurance marketplace), and CP.PMN.53 (Medicaid) when pursuing coverage for an unlisted indication.

    Key Clinical Thresholds and Dosing

    Age
    Minimum age≥ 18 years
    Age applicationApplies to adults with chronic kidney disease associated with type 2 diabetes
    Reference in criteriaListed as criterion I.A.2 for initial approval
    eGFR
    eGFR threshold for initiation≥ 25 mL/min/1.73 m2
    Dosing guidanceInitial dosing 10 mg or 20 mg PO QD based on eGFR and serum potassium thresholds; increase to target 20 mg PO QD after 4 weeks if parameters allow
    Role in criteria

    Prior Authorization, Documentation, and Alternatives

    Prior Authorization

    Prior authorization required — submit criteria documentation

    Prior authorization is required. Submit documentation demonstrating the member meets the initial approval criteria: diagnosis of CKD and type 2 diabetes, age ≥ 18 years, eGFR ≥ 25 mL/min/1.73 m2, UACR ≥ 30 mg/g, and requested dose not exceeding 20 mg/day and 1 tablet/day.

    • Include clinical evidence that all Initial Approval Criteria are met (diagnoses, age, eGFR, UACR, dose limits).
    Step Therapy

    Therapeutic alternatives — ACEi, ARB, SGLT2i listed

    Therapeutic alternatives listed in the policy include ACE inhibitors, ARBs, and SGLT2 inhibitors; the policy lists these alternatives but does not mandate a specific step-therapy sequence.

    • ACE inhibitors (examples and dose limits provided in Appendix B).
    • ARBs (examples and dose limits provided in Appendix B).
    • SGLT2 inhibitors (e.g., dapagliflozin 10 mg/day; empagliflozin 10–25 mg/day).

    Background and Drug Overview

    Finerenone (Kerendia) is a non‑steroidal mineralocorticoid receptor antagonist approved to reduce the risk of kidney and cardiovascular outcomes in adults with chronic kidney disease associated with type 2 diabetes. Dosing decisions are based on renal function and serum potassium, and the medication is provided as 10 mg and 20 mg tablets with a target maintenance dose of 20 mg once daily.

    For coverage purposes this policy requires patients to be adults (age ≥ 18 years) with chronic kidney disease and type 2 diabetes, have an estimated glomerular filtration rate of ≥ 25 mL/min/1.73 m2, and urine albumin‑to‑creatinine ratio of ≥ 30 mg/g. Dosing limits for approval are a maximum of 20 mg/day and no more than one tablet per day.

    Definitions and Drug Details

    Finerenone (Kerendia)
    Drug classNon-steroidal mineralocorticoid receptor antagonist
    Available strengthsTablets: 10 mg and 20 mg
    Primary indicationChronic kidney disease associated with type 2 diabetes to reduce risk of kidney and cardiovascular outcomes
    eGFR
    DefinitionEstimated glomerular filtration rate (eGFR)
    Initiation thresholdeGFR ≥ 25 mL/min/1.73 m2 required for initial approval
    Dosing implicationsInitial dose selection (10 mg or 20 mg PO QD) and increase to 20 mg after 4 weeks are determined by eGFR and serum potassium thresholds
    Policy Summary
    Payermeridian
    PolicyFinerenone (Kerendia) — Coverage Criteria for CKD with Type 2 Diabetes
    Policy CodePolicy MDN.CP.PMN.266
    Change TypeNo material changes
    Effective DateAug 1, 2025
    Last ReviewJul 9, 2025
    Next Review Date
    Key ActionSubmit documentation (office notes, lab results) demonstrating the member meets all approval criteria for prior authorization.
    SourceLink
    On This Page
    Coverage Criteria for Finerenone (Kerendia)Key Clinical Thresholds and DosingPrior Authorization, Documentation, and AlternativesBackground and Drug OverviewDefinitions and Drug Details
    Approval duration: Authorization duration: 12 months
    Required as part of initial approval (I.A.3.a)
    UACR
    UACR coverage threshold≥ 30 mg/g
    DefinitionUrine albumin-to-creatinine ratio (UACR)
    Role in criteriaRequired as part of initial approval (I.A.3.b)
    Dose limit
    Maximum daily dose20 mg per day
    Tablet limitNo more than 1 tablet per day
    Dosing targetTarget dose 20 mg PO QD (increase after 4 weeks based on eGFR and serum potassium)
  1. No explicit step-therapy ordering is required by this policy.
  2. Documentation Required

    Required documentation — labs and chart notes

    Providers must submit supporting clinical documentation such as office chart notes, laboratory results, or other clinical information that verify the member meets all approval criteria.

    • Office chart notes documenting CKD and type 2 diabetes diagnoses.
    • Recent eGFR value demonstrating ≥ 25 mL/min/1.73 m2.
    • Recent UACR result demonstrating ≥ 30 mg/g.
    • Prescription details showing requested dose ≤ 20 mg/day and ≤ 1 tablet/day.
    Denial Risk

    Denial risk — insufficient documentation or unsupported off‑label use

    Requests may be denied if submitted documentation does not demonstrate that the member meets all approval criteria or if the request is for a non‑FDA indication without off‑label policy support.

    • Insufficient or missing office notes, eGFR, or UACR results can lead to denial.
    • Non‑FDA indications require sufficient documentation per applicable off‑label use policies (commercial, marketplace, or Medicaid) or evidence of coverage.
    UACR
    DefinitionUrine albumin-to-creatinine ratio (UACR)
    Policy threshold for coverageUACR ≥ 30 mg/g required for initial approval
    Role in criteriaPart of renal function and albuminuria requirement (I.A.3.b)